TY - JOUR
T1 - Circulating tumor DNA
T2 - Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer
AU - Spindler, Karen Lise Garm
AU - Jakobsen, Anders
N1 - Publisher Copyright:
© The Author(s), 2023.
PY - 2023/1
Y1 - 2023/1
N2 - Interest in the measurement of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) has increased during the past decade. The analysis of quantitative ctDNA changes as a general response evaluation criterion during systemic treatment is a scientific approach with high clinical potential, and results can be transferred to a pan-cancer concept if relevantly investigated. The purpose of this overview is to discuss the current evidence for ctDNA as a marker of response in metastatic CRC (mCRC) and to propose criteria for definitions of response to systemic therapies applicable in prospective clinical trials. We discuss the literature, which supports a new definition of ctDNA Response Evaluation Criteria in Solid Tumors. Finally, we discuss the challenges in preparations of the optimal trial design to establish the true clinical utility of ctDNA.
AB - Interest in the measurement of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) has increased during the past decade. The analysis of quantitative ctDNA changes as a general response evaluation criterion during systemic treatment is a scientific approach with high clinical potential, and results can be transferred to a pan-cancer concept if relevantly investigated. The purpose of this overview is to discuss the current evidence for ctDNA as a marker of response in metastatic CRC (mCRC) and to propose criteria for definitions of response to systemic therapies applicable in prospective clinical trials. We discuss the literature, which supports a new definition of ctDNA Response Evaluation Criteria in Solid Tumors. Finally, we discuss the challenges in preparations of the optimal trial design to establish the true clinical utility of ctDNA.
KW - circulating tumor DNA
KW - clinical trial designs
KW - metastatic colorectal cancer
KW - response evaluation criteria
UR - http://www.scopus.com/inward/record.url?scp=85159109689&partnerID=8YFLogxK
U2 - 10.1177/17588359231171580
DO - 10.1177/17588359231171580
M3 - Review
C2 - 37152423
AN - SCOPUS:85159109689
SN - 1758-8340
VL - 15
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
ER -